TMO Stock Forecast & Price Target

Thermo Fisher Scientific is favored because its 3Q organic revenue growth of about 6% beat expectations, with adjusted EPS of $6.68 and operating margin expanding to 24.5%, showing both demand momentum and operating leverage. The upside was led by Lab Products and Biopharma Services, where revenue grew 10.0% organically on strong Patheon pharma services and research-and-safety demand, while Analytical Instruments grew about 6% and validated improving semiconductor-related activity. Management also raised FY26 revenue guidance to $47.7–$48.2B and EPS to $25.13–$25.43, supported by improving biotech funding, stable U.S. NIH demand, and continued market share gains that suggest a resilient, broadening recovery.

Thermo Fisher Scientific is facing a weak fundamental setup because investors have waited years for demand normalization in scientific lab supply, yet repeated false starts suggest end-market recovery may be delayed or absent. Its 2026 organic sales growth guidance of about 3%-4% remains far below the long-term 7% target, while 7%+ growth is viewed as aspirational and dependent on a broader turnaround that has not yet materialized. The stock also faces multiple compression risk if its past M&A-driven premium fades, especially as actionable targets have become scarcer and AI raises pressure on clinical research and core scientific supply businesses that together represent roughly 60% of sales.